{"id":3041,"date":"2016-10-27T06:30:00","date_gmt":"2016-10-27T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-interim-report-january-september-2016\/"},"modified":"2016-10-27T06:30:00","modified_gmt":"2016-10-27T06:30:00","slug":"xvivo-perfusion-interim-report-january-september-2016","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/","title":{"rendered":"XVIVO Perfusion Interim report January \u2013 September 2016"},"content":{"rendered":"
CONTINUED GROWTH AND POSITIVE OPERATING CASH-FLOW<\/strong><\/div>\n

THIRD QUARTER 2016 (JUL \u2013 SEP)<\/span><\/p>\n

\u2022 Net sales in the quarter amounted to SEK 31.7 (26.6) million, corresponding to an increase of 19 percent. The acquisition of Vivoline had a positive impact of SEK 1.6 million on sales. Adjusted for this, growth amounted to 13 percent in SEK and 12 in local currency.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding items effecting comparability increased by 22 percent and amounted to SEK 5.4 (4.4) million, corresponding to an EBITDA margin of 17 percent. Items effecting comparability of SEK 2.7 million related to the Nasdaq Stockholm main market listing and the acquisition of Vivoline have been charged against the quarter. EBITDA amounted to SEK 2.7 (4.4) million, corresponding to an EBITDA margin of 9 percent.
\u2022 Operating income amounted to SEK -0.7 (1.5) million, after amortization and depreciation of SEK 3.5 (2.9) million was charged against the quarter.
\u2022 Net income amounted to SEK -0.6 (1.3) million, resulting in earnings per share of SEK -0.02 (0.06).
\u2022 Cash flow from operating activities was SEK 5.4 (2.8) million.
\u2022 Total sales from warm perfusion (STEEN Solution\u2122, XPS\u2122, LS\u2122 and products and services related to the use of the XPS\u2122 and LS\u2122) accounted for 35 (29) percent of the total sales.
\u2022 2 XPS\u2122 contracts were signed in the USA during the quarter.
\u2022 During the quarter XVIVO Perfusion acquired another 1.6 percent of the shares and 0.7 percent of the 2015\/2016 warrants in the listed company Vivoline Medical AB, whereby XVIVO Perfusion became the owner of 98.6 percent of the shares and 99.6 percent of the warrants. The compulsory redemption process was initiated. Vivoline\u2019s shares and warrants were delisted from Nasdaq First north on July 8, 2016..<\/span><\/p>\n

THE PERIOD 2016 (JAN \u2013 SEP)<\/span><\/p>\n

\u2022 Net sales in the period amounted to SEK 99.8 (87.6) million, corresponding to an increase of 14 percent. The acquisitions of Vivoline had a positive impact of SEK 1.6 million on sales. Adjusted for this, growth amounted to 12 percent in SEK and 12 in local currency.
\u2022 Operating income before depreciation and amortization (EBITDA) excluding items effecting comparability increased by 45 percent and amounted to SEK 19.7 (13.6) million, corresponding to an EBITDA margin of 20 percent. Items effecting comparability of SEK 7.3 million related to the Nasdaq Stockholm main market listing and the acquisition of Vivoline have been charged against the period. EBITDA amounted to SEK 12.4 (11.9) million, corresponding to an EBITDA margin of 12 percent.
\u2022 Operating income amounted to SEK 2.7 (3.4) million, after amortization and depreciation of SEK 9.7 (8.5) million was charged against the period.
\u2022 Net income amounted to SEK 2.1 (2.3) million, resulting in earnings per share of SEK 0.09 (0.11).
\u2022 Cash flow from operating activities was SEK 18.7 (5.7) million.
\u2022 Total sales from warm perfusion (STEEN Solution\u2122, XPS\u2122, LS\u2122 and products and services related to the use of the XPS\u2122 and LS\u2122) accounted for 39 (38) percent of the total sales.
\u2022 During the period 6 XPS\u2122 were sold, of which 2 to Europe and 4 to the US. France and Switzerland were new countries that got access to the XPS\u2122 during the period.
\u2022 XVIVO Perfusion AB\u2019s shares were admitted for trading on Nasdaq First North Premier 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.<\/span><\/p>\n

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER <\/span><\/p>\n

\u2022 Two LS\u2122 contracts were signed in Spain after the end of the quarter.<\/span><\/p>\n

CONFERENCE CALL<\/span><\/p>\n

CEO Magnus Nilsson will present the report in a conference call at 3 p.m. CET on Thursday, October 27, 2016. Telephone: +44 (0) 2071 928 000, enter code 94108581.<\/span><\/p>\n

October 27, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO<\/span>\u00a0<\/p>\n

* LS-1 is the Vivoline EVLP machine.<\/span><\/p>\n

\n

For further information please contact:<\/span><\/p>\n

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com<\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/span><\/p>\n

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m<\/span>\u00a0CET on October 27, 2016.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CONTINUED GROWTH AND POSITIVE OPERATING CASH-FLOW THIRD QUARTER 2016 (JUL \u2013 SEP) \u2022 Net sales in the quarter amounted to…<\/p>\n","protected":false},"template":"","class_list":["post-3041","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q3","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar"],"acf":[],"yoast_head":"\nXVIVO Perfusion Interim report January \u2013 September 2016 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion Interim report January \u2013 September 2016 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"CONTINUED GROWTH AND POSITIVE OPERATING CASH-FLOW THIRD QUARTER 2016 (JUL \u2013 SEP) \u2022 Net sales in the quarter amounted to...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-september-2016\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-september-2016\\\/\",\"name\":\"XVIVO Perfusion Interim report January \u2013 September 2016 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-10-27T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-september-2016\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-september-2016\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-interim-report-january-september-2016\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion Interim report January \u2013 September 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion Interim report January \u2013 September 2016 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion Interim report January \u2013 September 2016 - XVIVO","og_description":"CONTINUED GROWTH AND POSITIVE OPERATING CASH-FLOW THIRD QUARTER 2016 (JUL \u2013 SEP) \u2022 Net sales in the quarter amounted to...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/","name":"XVIVO Perfusion Interim report January \u2013 September 2016 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-10-27T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-interim-report-january-september-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion Interim report January \u2013 September 2016"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}